Amylin Pharmaceuticals and Eli Lilly and Co. have terminated their exenatide alliance, resolving the outstanding litigation between the companies. Amylin will take full responsibility for the worldwide development and commercialization of Byetta (exenatide), starting in the U.S. on November 30, 2011, and extending to all markets by the end of 2013. “As pioneers in the GLP-1 market, we are proud of the truly innovative diabetes products that our two companies have provided patients,” said Daniel...